Mitigating Risk With Ex-US Clinical Trials

This presentation brings together industry leaders to explore how conducting clinical trials outside the U.S. can accelerate drug development and strengthen a company’s competitive position. Designed for biotech and mid-size pharmaceutical companies, especially CEOs, CMOs, and clinical development leaders, this session highlights key benefits of ex-US trials—including faster patient enrollment, more flexible regulatory pathways, and reduced operational risks. Experts from Novotech, Molecule to Medicine, ARENSIA, and Emeritus Research share real-world insights on selecting optimal regions and integrating global trial sites into a cohesive development plan. Moderated by Novotech’s VP of Drug Development Consulting, the discussion offers actionable strategies for streamlining timelines and enhancing investor confidence.